Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;13(5):422-427.
doi: 10.1097/COH.0000000000000489.

Ethical issues in HIV remission trials

Nir Eyal  1 , Lisa G Holtzman  1 , Steven G Deeks  2
Affiliations
Review

Ethical issues in HIV remission trials

Nir Eyal et al. Curr Opin HIV AIDS. 2018 Sep.

Abstract

Purpose of review: Several promising experimental pathways exist for long-term control of HIV in the absence of antiretroviral therapy (HIV 'remission') and are now being tested in early clinical studies. These studies can be invasive and pose a host of distinctive risks to participants, as well as to nonparticipants, especially to participants' fetuses, and sexual partners.

Recent findings: Ethical analyses of these studies have mainly focused on the risks to study participants. They recommend, and some investigators implement, procedures to mitigate risks for participants or to offset them with direct, indirect, and nonmedical benefits. They also suggest ways to keep participants' consent highly voluntary and informed. Rarely do ethicists propose keeping the social value of studies high. Of these recommended responses, only the latter, rarer proposals help address the risk to nonparticipants, as would some novel ways to address that risk.

Summary: HIV remission studies pose a number of ethical dilemmas. Many current investigative approaches put the participant at significant risk, but well established guidelines exist for mitigating this risk. Ethical issues that are not being fully addressed include risk to nonparticipants and the need to consider the societal value of studies, for example, their prospective impact on the global HIV burden. VIDEO ABSTRACT.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med 2016; 22:839–850. - PMC - PubMed

    2. A multidisciplinary, international group of experts working in the HIV cure arena defined ‘cure’, described current research and the ethical issues surrounding it, and developed a global strategy for HIV cure research.

    1. Eyal N, Kuritzkes DR. Challenges in clinical trial design for HIV-1 cure research. Lancet 2013; 382:1464–1465. - PubMed
    1. Evans D. What would you do to cure HIV? POZ. 2011; New York, USA: Susan Levey, Smart + Strong, Available from: http://www.aidsmeds.com/articles/hiv_cure_ethics_2042_20510.shtml. [Cited 2018].
    1. Rasmussen TA, Anderson JL, Wightman F, Lewin SR. Cancer therapies in HIV cure research. Curr Opin HIV AIDS 2017; 12:96–104. - PMC - PubMed

    2. Describes therapies for treatment of cancer that are now being tested in HIV remission studies, noting their toxicity risks.

    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443–2454. - PMC - PubMed

Publication types